Potential solutions for manufacture of CAR T cells in cancer immunotherapy

CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups.

Detalles Bibliográficos
Autores principales: Blache, Ulrich, Popp, Georg, Dünkel, Anna, Koehl, Ulrike, Fricke, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9445013/
https://www.ncbi.nlm.nih.gov/pubmed/36064867
http://dx.doi.org/10.1038/s41467-022-32866-0
Descripción
Sumario:CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups.

Ejemplares similares